Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin in the stratum corneum refers to a family of insoluble fibrous proteins, primarily types K1 and K10, that form the intermediate filament network within corneocytes—the dead, flattened cells composing the outermost barrier layer of the epidermis[1][2][3][7]. These keratins, arranged in a highly organized cubic rod-packing symmetry[citation needed from main structural models], provide the mechanical strength, elasticity, and water-holding properties that are critical for the stratum corneum's protective, hydration-retaining, and resilient functions[1][2][5][7]. Unlike receptors, enzymes, or transporters, keratin in this context is not a classical therapeutic molecular target, but its integrity is essential for skin barrier health and homeostasis. Dysfunction or abnormal structure of keratin and its associated matrix play a secondary role in the pathogenesis of several skin barrier disorders[1][4]. Clarification: - Is this a therapeutic target? No—keratin in the stratum corneum is a structural protein aggregate, not a traditional therapeutic target such as a receptor or enzyme. - Is the target formulation incorrect? Partially—while “keratin in the stratum corneum” is a real and critical component of the epidermal barrier, it is not a discrete druggable target, but rather a structural mixture and endpoint of keratinocyte differentiation. - Specific isoform? In the living epidermis, keratin isoforms (e.g., K1, K10) are expressed, but in the final stratum corneum, the protein is highly crosslinked and part of a complex, insoluble matrix[2][4]. Summary: Keratin in the stratum corneum is essential for skin structure and hydration, but is not a conventional molecular drug target[1][2][6]. No small molecules or biologics directly and selectively target this structural protein in situ. Disruption or alteration of keratin structure relates to skin barrier disease, but therapeutic intervention is indirect (e.g., emollients, barrier repair products)[1][6][7].
Not applicable (no drugs directly act via this molecule in its native, cornified form)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin in the stratum corneum.